226 related articles for article (PubMed ID: 20845961)
1. Synthesis and antitumor effect in vitro and in vivo of substituted 1,3-dihydroindole-2-ones.
Christensen MK; Erichsen KD; Trojel-Hansen C; Tjørnelund J; Nielsen SJ; Frydenvang K; Johansen TN; Nielsen B; Sehested M; Jensen PB; Ikaunieks M; Zaichenko A; Loza E; Kalvinsh I; Björkling F
J Med Chem; 2010 Oct; 53(19):7140-5. PubMed ID: 20845961
[TBL] [Abstract][Full Text] [Related]
2. Quinols as novel therapeutic agents. 2.(1) 4-(1-Arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and related agents as potent and selective antitumor agents.
Berry JM; Bradshaw TD; Fichtner I; Ren R; Schwalbe CH; Wells G; Chew EH; Stevens MF; Westwell AD
J Med Chem; 2005 Jan; 48(2):639-44. PubMed ID: 15658878
[TBL] [Abstract][Full Text] [Related]
3. Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives.
Cho TP; Dong SY; Jun F; Hong FJ; Liang YJ; Lu X; Hua PJ; Li LY; Lei Z; Bing H; Ying Z; Qiong LF; Bei FB; Guang LL; Shen GA; Hong SG; Hong SW; Tai MX
J Med Chem; 2010 Nov; 53(22):8140-9. PubMed ID: 21028894
[TBL] [Abstract][Full Text] [Related]
4. Antitumor agents 253. Design, synthesis, and antitumor evaluation of novel 9-substituted phenanthrene-based tylophorine derivatives as potential anticancer agents.
Wei L; Shi Q; Bastow KF; Brossi A; Morris-Natschke SL; Nakagawa-Goto K; Wu TS; Pan SL; Teng CM; Lee KH
J Med Chem; 2007 Jul; 50(15):3674-80. PubMed ID: 17585747
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.
Leese MP; Jourdan FL; Gaukroger K; Mahon MF; Newman SP; Foster PA; Stengel C; Regis-Lydi S; Ferrandis E; Di Fiore A; De Simone G; Supuran CT; Purohit A; Reed MJ; Potter BV
J Med Chem; 2008 Mar; 51(5):1295-308. PubMed ID: 18260615
[TBL] [Abstract][Full Text] [Related]
6. A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
Sato A; McNulty L; Cox K; Kim S; Scott A; Daniell K; Summerville K; Price C; Hudson S; Kiakos K; Hartley JA; Asao T; Lee M
J Med Chem; 2005 Jun; 48(11):3903-18. PubMed ID: 15916443
[TBL] [Abstract][Full Text] [Related]
7. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
8. A novel class of achiral seco-analogs of CC-1065 and the duocarmycins: design, synthesis, DNA binding, and anticancer properties.
Kupchinsky S; Centioni S; Howard T; Trzupek J; Roller S; Carnahan V; Townes H; Purnell B; Price C; Handl H; Summerville K; Johnson K; Toth J; Hudson S; Kiakos K; Hartley JA; Lee M
Bioorg Med Chem; 2004 Dec; 12(23):6221-36. PubMed ID: 15519165
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
Moffat D; Patel S; Day F; Belfield A; Donald A; Rowlands M; Wibawa J; Brotherton D; Stimson L; Clark V; Owen J; Bawden L; Box G; Bone E; Mortenson P; Hardcastle A; van Meurs S; Eccles S; Raynaud F; Aherne W
J Med Chem; 2010 Dec; 53(24):8663-78. PubMed ID: 21080647
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antitumor activity of duocarmycin derivatives: modification of segment-A of A-ring pyrrole compounds.
Amishiro N; Okamoto A; Murakata C; Tamaoki T; Okabe M; Saito H
J Med Chem; 1999 Jul; 42(15):2946-60. PubMed ID: 10425104
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and antitumor activities of a series of novel quinoxalinhydrazides.
Grande F; Aiello F; Grazia OD; Brizzi A; Garofalo A; Neamati N
Bioorg Med Chem; 2007 Jan; 15(1):288-94. PubMed ID: 17085054
[TBL] [Abstract][Full Text] [Related]
12. Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
Helsby NA; Atwell GJ; Yang S; Palmer BD; Anderson RF; Pullen SM; Ferry DM; Hogg A; Wilson WR; Denny WA
J Med Chem; 2004 Jun; 47(12):3295-307. PubMed ID: 15163209
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
14. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.
Drees M; Dengler WA; Roth T; Labonte H; Mayo J; Malspeis L; Grever M; Sausville EA; Fiebig HH
Clin Cancer Res; 1997 Feb; 3(2):273-9. PubMed ID: 9815683
[TBL] [Abstract][Full Text] [Related]
15. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
[TBL] [Abstract][Full Text] [Related]
16. Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine.
Cohen F; Bergeron P; Blackwood E; Bowman KK; Chen H; Dipasquale AG; Epler JA; Koehler MF; Lau K; Lewis C; Liu L; Ly CQ; Malek S; Nonomiya J; Ortwine DF; Pei Z; Robarge KD; Sideris S; Trinh L; Truong T; Wu J; Zhao X; Lyssikatos JP
J Med Chem; 2011 May; 54(9):3426-35. PubMed ID: 21495671
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of 4/5-hydroxy-2,3-diaryl(substituted)-cyclopent-2-en-1-ones as cis-restricted analogues of combretastatin A-4 as novel anticancer agents.
Gurjar MK; Wakharkar RD; Singh AT; Jaggi M; Borate HB; Shinde PD; Verma R; Rajendran P; Dutt S; Singh G; Sanna VK; Singh MK; Srivastava SK; Mahajan VA; Jadhav VH; Dutta K; Krishnan K; Chaudhary A; Agarwal SK; Mukherjee R; Burman AC
J Med Chem; 2007 Apr; 50(8):1744-53. PubMed ID: 17373779
[TBL] [Abstract][Full Text] [Related]
18. 4- and 5-aroylindoles as novel classes of potent antitubulin agents.
Liou JP; Wu CY; Hsieh HP; Chang CY; Chen CM; Kuo CC; Chang JY
J Med Chem; 2007 Sep; 50(18):4548-52. PubMed ID: 17685504
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of imidazol-2-one derivatives as potential antitumor agents.
Xue N; Yang X; Wu R; Chen J; He Q; Yang B; Lu X; Hu Y
Bioorg Med Chem; 2008 Mar; 16(5):2550-7. PubMed ID: 18226907
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives. Part 2.
Tseng CH; Tzeng CC; Yang CL; Lu PJ; Chen HL; Li HY; Chuang YC; Yang CN; Chen YL
J Med Chem; 2010 Aug; 53(16):6164-79. PubMed ID: 20662543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
